EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome

Kittipos Visitsunthorn, V Koneti Rao

The Journal of Allergy and Clinical Immunology: In Practice · 2026-07 · 14 (7) · 1525-1528

DOI: 10.1016/j.jaip.2026.03.040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-07. Verfasst von Kittipos Visitsunthorn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Lymphoproliferative Disorders, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activated phosphoinositide 3-kinase delta syndrome is an inborn error of immunity characterized by combination of immunodeficiency with immune dysregulation and classified within autoimmune lymphoproliferative immunodeficiencies. Early therapeutic strategies extrapolated from autoimmune lymphoproliferative syndrome, including mTOR inhibition with sirolimus, provided variable control of lymphoproliferation. Recognition of constitutive PI3Kδ signaling led to the development of leniolisib, approved by the U.S. Food and Drug Administration in 2023, marking a transition toward pathway-specific precision therapy. In this Clinical Perspective, we review the evolution of targeted therapy in APDS, the biochemical structure and selectivity of leniolisib relative to other PI3K inhibitors, and the mechanistic distinction between proximal PI3Kδ inhibition and downstream mTOR blockade. We summarize current clinical evidence and practical considerations for dosing and monitoring in the absence of serum drug-level assays. Finally, we outline key unresolved questions, including long-term disease modification, biomarker validation, pediatric outcomes, treatment sequencing and combination strategies, while positioning leniolisib relative to hematopoietic stem cell transplantation, and desirability of it’s wider global access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesLymphoproliferative DisordersPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsHumansAnimalsTOR Serine-Threonine KinasesMTOR InhibitorsSignal TransductionPrimary Immunodeficiency Diseases

Stichwörter der Autor:innen

APDSInborn error of immunityLeniolisibPI3K deltaPrecision therapy

Substanzen

Class I Phosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsMTOR InhibitorsProtein Kinase InhibitorsMTOR protein, human

Autor:innen und Institutionen

  • Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: korao@nih.gov.

Förderung

  • Intramural NIH HHS
  • National Institutes of Health

Zitieren

APA

Visitsunthorn, K., & Rao, V. K. (2026). Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome. The Journal of Allergy and Clinical Immunology: In Practice, 14(7), 1525-1528. https://doi.org/10.1016/j.jaip.2026.03.040

Vancouver

Visitsunthorn K, Rao VK. Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(7):1525-1528. doi:10.1016/j.jaip.2026.03.040

BibTeX
@article{Visitsunthorn2026,
  author = {Visitsunthorn, Kittipos and Rao, V Koneti},
  title = {Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {1525--1528},
  doi = {10.1016/j.jaip.2026.03.040}
}
Kostenlos starten →